Anterogen.Co.,Ltd.
KOSDAQTotal Valuation
Anterogen.Co.,Ltd. carries a market capitalization of 153.59B, placing it among publicly traded companies globally. Its enterprise value stands at 387.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 153.59B |
| Enterprise Value | 387.36B |
Share Statistics
Anterogen.Co.,Ltd. currently has 10.01M shares outstanding.
| Shares Outstanding | 10.01M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 53.37, and the price-to-book ratio stands at -56.26.
| PE Ratio | N/A |
| PS Ratio | 53.37 |
| PB Ratio | -56.26 |
| P/TBV Ratio | 5.54 |
| P/FCF Ratio | -436.51 |
| P/OCF Ratio | -344.00 |
Enterprise Valuation
| EV / Sales | 48.08 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Anterogen.Co.,Ltd. maintains a current ratio of 63.40, meaning it holds 63.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 63.40 |
| Quick Ratio | 56.94 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -1.72 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.99 |
Stock Price Statistics
Anterogen.Co.,Ltd.'s stock has declined approximately -44.18182% over the past 52 weeks. The 50-day moving average sits at 28,053.80, while the 200-day moving average is 33,379.20.
| Beta (5Y) | N/A |
| 52-Week Price Change | -44.18182% |
| 50-Day Moving Average | 28,053.80 |
| 200-Day Moving Average | 33,379.20 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Anterogen.Co.,Ltd. generated 8.06B in revenue and converted that into -1.56B in net income, yielding earnings per share of -155.54. EBITDA reached -2.44B, while operating income came in at -2.44B.
| Revenue | 8.06B |
| Gross Profit | 2.83B |
| Operating Income | -2.44B |
| Pretax Income | -1.28B |
| Net Income | -1.56B |
| EBITDA | -2.44B |
| EBIT | -2.44B |
| Earnings Per Share (EPS) | -155.54 |
Balance Sheet
Total book value stands at -7.64B, with working capital of 46.78B providing operational flexibility.
| Cash & Cash Equivalents | 42.68B |
| Total Debt | N/A |
| Net Debt | -1.68B |
| Equity (Book Value) | -7.64B |
| Book Value Per Share | -763.41 |
| Working Capital | 46.78B |
Cash Flow
Anterogen.Co.,Ltd. produced -1.25B in operating cash flow over the past twelve months. After subtracting -264.92M in capital expenditures, free cash flow totaled -1.52B - equivalent to -151.31 per share.
| Operating Cash Flow | -1.25B |
| Capital Expenditures | -264.92M |
| Free Cash Flow | -1.52B |
| FCF Per Share | -151.31 |
Margins
Anterogen.Co.,Ltd. operates with a gross margin of 35.11, reflecting its pricing power and cost economics. The operating margin of -30.25 and net profit margin of -19.33 provide insight into operational efficiency.
| Gross Margin | 35.11 |
| Operating Margin | -30.25 |
| Pretax Margin | -15.86 |
| Profit Margin | -19.33 |
| EBITDA Margin | -30.25 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -0.23 |
Scores
Anterogen.Co.,Ltd. posts an Altman Z-Score of 269.57, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 269.57 |